mediVR

mediVR operates at the intersection of medical devices, rehabilitation, and virtual reality, with mediVR Kagura as its central product. The device is described as supporting rehabilitation through VR-guided movement and cognitive tasks, including exercises performed while seated. Its quantitative assessment of task achievement and movement targets is a specific point of distinction from a general-purpose VR experience: the stated use is to help rehabilitation professionals assess performance and adjust training difficulty. The company also describes its approach as somatic-cognitive coordination therapy, linking physical movement with cognitive engagement. Its relevant competitive arena is therefore best understood as VR-enabled rehabilitation and medical-device-led neurorehabilitation, where clinical evidence, usability in care settings, and measurable outcomes matter. A 2026 paper in Neurology and selection for the MedTech Innovator Asia Pacific accelerator add research and ecosystem signals, but do not by themselves establish comparative clinical superiority or commercial scale.

mediVR was founded in 2016 and has developed a focused rehabilitation-device business around mediVR Kagura. Its recorded funding history includes a ¥40 million Seed round in September 2018, a ¥290 million round in December 2019, and a ¥500 million Series B in July 2021, led by MedVenture Partners. Additional financial signals list a ¥280 million Series C in February 2025. Those amounts indicate continued capital formation, although the round history and reported aggregate funding do not fully reconcile: the aggregate is $7,203,698 and corresponds to the two rounds represented in the structured funding total, while the broader round list includes four rounds. In 2026, publication of SCCT-related research in Neurology and selection for a 20-company APAC accelerator cohort from more than 680 applicants mark two distinct milestones—academic recognition and startup-program access. The company is listed in the 11–50 employee range.